The Alzheimer’s Association
Transforming Alzheimer’s Disease Therapies Through Collaboration

James Hendrix, PhD
Director, Global Science Initiatives
The Alzheimer’s Epidemic Continues to Grow

5.3 million Americans of **ALL** Ages will have Alzheimer’s in 2015

6 **TH LEADING CAUSE OF DEATH IN THE U.S.**

Of the top 10 killers, Alzheimer’s is the only one that cannot be prevented, cured or even slowed.

Total cost of care for those with Alzheimer’s, with more than two-thirds paid by Medicare and Medicaid.

Source: Centers for Disease Control and Prevention (cdc.gov/chronicdisease/leading-causes-of-death.html)
Alzheimer’s Crisis In the Baby Boom Generation

• If no way to stop or slow the progression of the disease ….
  • More than 28 million Baby Boomers will develop Alzheimer’s by 2050
  • Will account for nearly 25% of Medicare spending by 2050

Prevalence of Alzheimer’s among Baby Boomers

![Graph showing the increase in prevalence of Alzheimer's among Baby Boomers from 2020 to 2050.](image-url)
Alzheimer’s Association
Public Private Partnerships

iDEAS
Imaging Dementia—Evidence For Amyloid Scanning

ADNI

THE biomarkers CONSORTIUM

DIAN TU
Dominantly Inherited Alzheimer Network Trials Unit

ALZHEIMER’S PREVENTION INITIATIVE
LEARN

• Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN)

• Natural history study of 400 people with low/intermediate levels of amyloid

• Leveraging the A4 trial
  
  • **Largest award ever given by Alzheimer’s Association**
  
  • **First funded tau imaging study**

JT Chien et al. Journal of Alz Dis 2013
Grant Partnerships: Biomarkers Across Neurodegenerative Diseases (BAND)

- GOAL: To stimulate analyses across Alzheimer’s and Parkinson’s to engage in further data analysis of existing research information to advance biomarker discovery, standardization of assays, genetic profiles, and imaging modalities.
- Leverage data from ADNI and PPMI
- First of its kind collaboration with Michael J. Fox Foundation & Weston Brain Institute
- Awarded 9 projects
Grant Partnerships: Mechanisms of Cellular Death in Neurodegeneration (MEND)

• GOAL: To discover and understand mechanisms and pathophysiological processes by which brain cell loss is mediated in disease and thereby seek insights and potential targets for therapeutic interventions that would sustain healthy brain function.

• Funding international from funding organizations in three countries

• Awards to be announced by 10/30

• Alz.org/MEND
Technology and Dementia

Technology Professional Interest Area (PIA)
IDEAS (Imaging Dementia Evidence for Amyloid Scanning) STUDY

- 4-year, $100 million Alzheimer’s research
- Alzheimer’s Association and American College of Radiology (ACR).
- Goal: To determine clinical usefulness, value in diagnosing Alzheimer’s (and other dementias) of a brain PET scan that detects amyloid plaques – a core feature of AD.
- 18,488 Medicare beneficiaries, age 65 or older, who have uncertain diagnosis will be enrolled over 24 months at approximately 200 sites throughout the United States.
- Data from this study will help determine if Medicare will reimburse the cost of amyloid PET scans for diagnostically uncertain cases. Medicare does not currently cover amyloid PET scans.

Image adapted from Clark et al. (2011) JAMA 305(1).
Vision for the Future

• Advances in understanding of AD progression via new biomarkers (i.e. Tau PET, Neurogranin, etc.)
• Expansion of open access data
• New treatment strategies (i.e. AD Prevention, Combination Therapy)
• New therapeutics coming?
THE END OF ALZHEIMER'S STARTS WITH YOU

alzheimer's association

alz.org